Modena, Inc. said Nov. 30 that it will apply for an emergency use authorization for the neo-crown pneumonia vaccine in the U.S. and Europe, and that complete results from its vaccine trials show 94.1 percent effectiveness against the neo-crown virus with no serious safety concerns.
Modena CEO Bensel said: “Our vaccine will be a new and powerful tool that can change the general trend of the epidemic and prevent severe illness, hospitalization and death.”
If the Modena vaccine is approved by the U.S. Food and Drug Administration (FDA) as safe and effective, it could be available in the U.S. by mid-December. Pfizer has applied for an emergency use authorization last week, which could be granted after Dec. 10. U.S. Health Secretary Henry Achar said on December 30 that Pfizer and Modena vaccines could be available in the U.S. by Christmas.
Modena has been clinically tested on 30,000 subjects, 15,000 of whom received the Modena vaccine and the rest a placebo. So far there have been no serious side effects. Of the group given a placebo, 185 people were infected, some of whom were seriously ill. By contrast, in the vaccinated group, 11 people were infected, and none of them were seriously ill. Modena also reported results showing a 100% success rate of its vaccine against severe illness.
The UK is reviewing Pfizer Vaccine’s New Crown vaccine in collaboration with Oxford University and Astellitec Pharmaceuticals.
The Oxford vaccine is cheaper, costing about $4 for a dose; Pfizer costs $20; and Modena costs $33. However, the effectiveness rate of the Oxford vaccine in clinical trials ranges from 62% to 90%, which is lower than that of Pfizer and Modena.
Recent Comments